Checkpoint therapies like Keytruda, Opdivo, and Imfinzi are expanding from late-stage to early-stage cancer treatment, with ...

AstraZeneca is planting its flag in the oral SERD space, touting positive Phase 3 breast cancer data for a program it expects ...

Immatics has shared new survival data from a Phase 1b trial of its melanoma cell therapy candidate, bolstering expectations for a registrational study that it recently started.

Summit Therapeutics’ mixed results for its potential competitor to Merck’s Keytruda left an important question unanswered: ...

Adding Pfizer’s BRAF inhibitor Braftovi to a cocktail of cancer drugs cut the risk of death for certain colorectal cancer ...

Biopharma faces uncertainty in H2 2025 amid policy concerns and market challenges, with key healthcare conferences and ...

Summit Therapeutics' ivonescimab shows 48% PFS benefit but misses OS endpoint in Phase 3 lung cancer trial; drug's regulatory ...

Sinema has backed a bill advancing in the Arizona legislature that would include a $5 million grant to a neurological ...

Novo Nordisk warned the US government not to impose pharma-specific tariffs, but instead to tax illegal importers of ...

Astellas is the latest large pharmaceutical company to ink a deal with a Chinese biotech, paying $130 million upfront for a ...

The US Supreme Court will continue deciding whether to take up a pivotal case on state PBM regulation after the federal ...